| 2025年年报 | 2025年三季报 | 2025年中报 | 2024年年报 | 2024年三季报 | 2024年中报 | |
|---|---|---|---|---|---|---|
| 营业收入(元) | ||||||
| 基因编辑业务(元) | - | 57,143,976.80 | 28,617,300.00 | 72,083,300.00 | 50,737,275.02 | 34,606,200.00 |
| 抗体开发业务(元) | - | 201,291,486.79 | 162,862,800.00 | 317,794,000.00 | 143,401,364.05 | 118,199,600.00 |
| 临床前药理药效评价(元) | - | 233,382,233.56 | 155,030,800.00 | 200,989,100.00 | 116,008,605.33 | 81,551,600.00 |
| 模式动物销售(元) | - | 449,012,141.49 | 274,425,900.00 | 389,204,400.00 | 279,365,862.10 | 175,772,200.00 |
| 基因编辑(元) | 72,018,179.09 | - | - | - | - | - |
| 抗体开发(元) | 332,352,992.24 | - | - | - | - | - |
| 模式动物(元) | 622,182,399.28 | - | - | - | - | - |
| 药理药效(元) | 352,203,376.03 | - | - | - | - | - |
| 营业成本(元) | ||||||
| 基因编辑业务(元) | - | - | 19,549,100.00 | 30,754,200.00 | - | 15,269,400.00 |
| 抗体开发业务(元) | - | - | 11,881,000.00 | 22,770,000.00 | - | 10,823,600.00 |
| 临床前药理药效评价(元) | - | - | 70,644,700.00 | 83,561,600.00 | - | 37,600,400.00 |
| 模式动物销售(元) | - | - | 56,939,700.00 | 81,670,200.00 | - | 41,133,800.00 |
| 基因编辑(元) | 28,768,234.72 | - | - | - | - | - |
| 抗体开发(元) | 46,522,158.99 | - | - | - | - | - |
| 模式动物(元) | 121,903,957.84 | - | - | - | - | - |
| 药理药效(元) | 136,023,815.24 | - | - | - | - | - |
| 毛利(元) | ||||||
| 基因编辑业务(元) | - | - | 9,068,200.00 | 41,329,100.00 | - | 19,336,800.00 |
| 抗体开发业务(元) | - | - | 150,981,800.00 | 295,024,000.00 | - | 107,376,000.00 |
| 临床前药理药效评价(元) | - | - | 84,386,100.00 | 117,427,500.00 | - | 43,951,200.00 |
| 模式动物销售(元) | - | - | 217,486,200.00 | 307,534,200.00 | - | 134,638,400.00 |
| 基因编辑(元) | 43,249,944.37 | - | - | - | - | - |
| 抗体开发(元) | 285,830,833.25 | - | - | - | - | - |
| 模式动物(元) | 500,278,441.44 | - | - | - | - | - |
| 药理药效(元) | 216,179,560.79 | - | - | - | - | - |
| 毛利率(%) | ||||||
| 基因编辑业务(%) | - | - | 31.69 | 57.34 | - | 55.88 |
| 抗体开发业务(%) | - | - | 92.70 | 92.83 | - | 90.84 |
| 临床前药理药效评价(%) | - | - | 54.43 | 58.42 | - | 53.89 |
| 模式动物销售(%) | - | - | 79.25 | 79.02 | - | 76.60 |
| 基因编辑(%) | 60.05 | - | - | - | - | - |
| 抗体开发(%) | 86.00 | - | - | - | - | - |
| 模式动物(%) | 80.41 | - | - | - | - | - |
| 药理药效(%) | 61.38 | - | - | - | - | - |
| 收入构成(%) | ||||||
| 基因编辑业务(%) | - | 6.07 | 4.61 | 7.35 | 8.61 | 8.44 |
| 抗体开发业务(%) | - | 21.40 | 26.23 | 32.43 | 24.33 | 28.82 |
| 临床前药理药效评价(%) | - | 24.81 | 24.97 | 20.51 | 19.68 | 19.88 |
| 模式动物销售(%) | - | 47.73 | 44.20 | 39.71 | 47.39 | 42.86 |
| 基因编辑(%) | 5.22 | - | - | - | - | - |
| 抗体开发(%) | 24.11 | - | - | - | - | - |
| 模式动物(%) | 45.13 | - | - | - | - | - |
| 药理药效(%) | 25.54 | - | - | - | - | - |
| 毛利构成(%) | ||||||
| 基因编辑业务(%) | - | - | 1.96 | 5.43 | - | 6.33 |
| 抗体开发业务(%) | - | - | 32.69 | 38.75 | - | 35.17 |
| 临床前药理药效评价(%) | - | - | 18.27 | 15.42 | - | 14.40 |
| 模式动物销售(%) | - | - | 47.08 | 40.40 | - | 44.10 |
| 基因编辑(%) | 4.14 | - | - | - | - | - |
| 抗体开发(%) | 27.34 | - | - | - | - | - |
| 模式动物(%) | 47.85 | - | - | - | - | - |
| 药理药效(%) | 20.68 | - | - | - | - | - |